Latest news with #DanielArias
Yahoo
15-07-2025
- Business
- Yahoo
Waters, BD Bioscience deal ‘looks to be a good fit,' says Stifel
Waters (WAT) announced that it is combining with BD's (BDX) Bioscience and Diagnostics business in a tax-efficient Reverse Morris Trust transaction that is valued at roughly $17.5B, marking a major strategic step for Waters, as the deal is large and transformative, Stifel analyst Daniel Arias tells investors in a research note. The move looks to be a good fit, though the size and complexity of the deal has to be acknowledged, Stifel says. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on WAT: Disclaimer & DisclosureReport an Issue Waters falls -9.0% Waters sinks 12% to $312.06 following combination with Becton unit Hold Rating on Waters-Becton Merger: Strategic Growth vs. Valuation Concerns Waters, BD's Biosciences & Diagnostic Solutions business to combine Waters Announces $17.5B Merger with BD's Biosciences
Yahoo
10-05-2025
- Business
- Yahoo
Illumina price target lowered to $135 from $160 at Stifel
Stifel analyst Daniel Arias lowered the firm's price target on Illumina (ILMN) to $135 from $160 and keeps a Buy rating on the shares. Illumina posted a 'nice' Q1 beat and then reduced the FY25 guidance, as expected, the analyst tells investors. The cut to the top-line 'was maybe a point or so deeper than we thought it might be,' but the EPS outlook is better than the firm anticipated thanks to strong mitigation activities, the analyst added. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on ILMN: Disclaimer & DisclosureReport an Issue Illumina price target raised to $89 from $86 at TD Cowen Illumina price target lowered to $85 from $120 at JPMorgan Illumina price target lowered to $114 from $122 at Guggenheim Illumina's Financial Outlook: Hold Rating Amidst Export Bans and Tariff Challenges Illumina Reports Q1 2025 Financial Results Amid Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
